We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 29

European Commission proposes regulation on access to genetic resources

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • October 18 2012

To carry out European Union (EU) obligations under the Nagoya Protocol on Access to Genetic Resources and Benefit-Sharing, the European Commission (EC) has proposed a regulation that would ensure that only legally acquired genetic resources and associated traditional knowledge are used in the EU and that such resources are fairly and equitably shared

EU adds pharmaceuticals to water pollution watch list

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • July 11 2013

The European Commission (EC) has added 12 new substances to the European Union's (EU's) priority list of chemicals known to pose a risk to the safety

EU legal services opinion could upset proposed GM laws

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • November 18 2010

According to media sources, the EU Council of Ministers' Legal Service has expressed "strong doubts" about the feasibility of a proposal that would allow individual member states to set their own policies for regulating genetically modified (GM) crops

News bytes

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • December 16 2010

The European Medicines Agency (EMA) adopts two draft guidelines as part of the regulatory approval process for certain biosimilar medicinal products

Report suggests Europe could become marine biotech leader by 2020

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • January 13 2011

The Marine Board of the European Science Foundation has released a report that suggests Europe could become a global leader in marine biotechnology by 2020, particularly by cultivating microalgae for fuel

Joint public meeting to focus on bridging nanotechnology research

  • Shook Hardy & Bacon LLP
  • -
  • European Union, USA
  • -
  • February 24 2011

The National Nanotechnology Coordination Office has announced that it will spearhead a public meeting to focus on "environmental health and safety questions for nanomaterials and nanotechnology-enabled products" and to "encourage joint US-EU programs of work that would leverage resources."

Europe sees strong growth in biotech patent filings

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • April 21 2011

According to a news source, biotechnology patent applications filed with the European Patent Organization (EPO) grew more than 42 percent in 2010 from the previous year

Researchers protest ECJ advocate general’s position on patenting stem cell technologies

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • May 5 2011

Viewing the issue as a matter of morality, the advocate general of the European Court of Justice (ECJ) recently delivered a non-binding ruling that would render unpatentable the cells removed from the human embryo at the blastocyst stage, because the removal involves the embryo's destruction

EU Court of Justice nixes patents for stem-cell inventions involving human embryo destruction

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • October 20 2011

The European Union (EU) Court of Justice has determined that EU patent law does not protect neural precursor cells and the processes for their production from embryonic stem cells

European Medicines Agency considers changes to biosimilar guidelines

  • Shook Hardy & Bacon LLP
  • -
  • European Union
  • -
  • October 20 2011

The European Medicines Agency (EMA) has published a concept paper outlining a number of clinical and non-clinical issues that need revision in its current “Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance"